No. |
Drug (Description in trials) |
DrugBank |
KEGG DRUG * |
KEGG GENES * [Number of genes] |
KEGG PATHWAY [Number of pathways] |
Disease ID * [Number of diseases] |
1 |
1-deoxynojirimycin |
Duvoglustat |
D09605 |
[1] GAA |
[4] Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism |
[1] 256 |
2 |
1-deoxynojirimycin hydrochloride |
Duvoglustat |
D09605 |
[1] GAA |
[4] Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism |
[1] 256 |
3 |
Aav2/8lsphgaa |
- |
- |
- |
- |
[1] 256 |
4 |
Acetaminophen |
Acetaminophen |
D00217 |
[2] PTGS1, PTGS2 |
[21] Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
[11] 13, 34, 35, 46, 49, 51, 70, 86, 231, 256, 271 |
5 |
Acid alpha glucosidase |
Alglucosidase alfa |
D03207 |
[1] GAA |
[4] Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism |
[1] 256 |
6 |
Albuterol |
Salbutamol |
D02147 |
[1] ADRB2 |
[8] Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
[8] 12, 13, 86, 89, 113, 231, 256, 299 |
7 |
Alglucosidase alfa |
Alglucosidase alfa |
D03207 |
[1] GAA |
[4] Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism |
[1] 256 |
8 |
Alglucosidase alfa (gz419829) |
Alglucosidase alfa |
D03207 |
[1] GAA |
[4] Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism |
[1] 256 |
9 |
Alglucosidase alfa (myozyme) |
Alglucosidase alfa |
D03207 |
[1] GAA |
[4] Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism |
[1] 256 |
10 |
Alglucosidase alfa (recombinant human acid alpha-glucosidase [rhgaa]) |
Alglucosidase alfa |
D03207 |
[1] GAA |
[4] Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism |
[1] 256 |
11 |
Alglucosidase alfa gz419829 |
Alglucosidase alfa |
D03207 |
[1] GAA |
[4] Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism |
[1] 256 |
12 |
Alglucosidase alpha |
- |
- |
- |
- |
[1] 256 |
13 |
Alpha glucosidase |
Alglucosidase alfa |
D03207 |
[1] GAA |
[4] Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism |
[1] 256 |
14 |
Alpha-glucosidase |
Alglucosidase alfa |
D03207 |
[1] GAA |
[4] Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism |
[1] 256 |
15 |
At2220 |
At2220 |
- |
- |
- |
[1] 256 |
16 |
At2221 |
- |
- |
- |
- |
[1] 256 |
17 |
Atb200 |
- |
- |
- |
- |
[1] 256 |
18 |
Avalglucosidase alfa gz402666 |
- |
- |
- |
- |
[1] 256 |
19 |
Avalglucosidase alfa(gz402666) |
- |
- |
- |
- |
[1] 256 |
20 |
Beta-hydroxybuturate esters |
- |
- |
- |
- |
[1] 256 |
21 |
Bmn 701 |
- |
- |
- |
- |
[1] 256 |
22 |
Bortezomib |
Bortezomib |
D03150 |
[1] PSMB5 |
[1] Proteasome |
[13] 11, 26, 28, 46, 49, 51, 61, 63, 66, 228, 256, 288, 331 |
23 |
Clenbuterol |
Clenbuterol |
D07713 |
[1] ADRB2 |
[8] Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
[2] 1, 256 |
24 |
Deoxynojirimycin |
Duvoglustat |
D09605 |
[1] GAA |
[4] Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism |
[1] 256 |
25 |
Deprakine |
- |
- |
- |
- |
[1] 256 |
26 |
Diphenhydramine |
Diphenhydramine |
D00300, D00669, D02419, D03285, D03360, D03854 |
[1] HRH1 |
[3] Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
[5] 49, 51, 70, 86, 256 |
27 |
Duvoglustat |
Duvoglustat |
D09605 |
[1] GAA |
[4] Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism |
[1] 256 |
28 |
Duvoglustat hcl |
Duvoglustat |
D09605 |
[1] GAA |
[4] Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism |
[1] 256 |
29 |
Duvoglustat hydrochloride |
Duvoglustat |
D09605 |
[1] GAA |
[4] Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism |
[1] 256 |
30 |
Enzyme replacement agent |
- |
- |
- |
- |
[1] 256 |
31 |
Epilim chrono 200 controlled released tablets |
- |
- |
- |
- |
[1] 256 |
32 |
Epilim chrono 300 controlled released tablets |
- |
- |
- |
- |
[1] 256 |
33 |
Epilim chrono 500 controlled released tablets |
- |
- |
- |
- |
[1] 256 |
34 |
Glucosidase alfa |
- |
- |
- |
- |
[1] 256 |
35 |
Glycosade |
- |
- |
- |
- |
[3] 65, 256, 257 |
36 |
Gz402666 |
- |
- |
- |
- |
[1] 256 |
37 |
Intravenous immune globulin |
- |
- |
- |
- |
[1] 256 |
38 |
Lidocaine |
Lidocaine |
D00358, D02086, D08127 |
[5] SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
[3] Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
[8] 6, 13, 46, 86, 168, 226, 231, 256 |
39 |
Lmx 4 topical cream |
- |
- |
- |
- |
[1] 256 |
40 |
Mannose |
Mannose |
- |
- |
- |
[2] 13, 256 |
41 |
Methotrexate |
Methotrexate |
D00142, D02115 |
[2] DHFR, DHFR2 |
[4] Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
[33] 11, 13, 19, 34, 35, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 162, 164, 172, 256, 271, 284, 285, 326, 331 |
42 |
Miglustat |
Miglustat |
D05032 |
[1] UGCG |
[2] Metabolic pathways, Sphingolipid metabolism |
[3] 19, 256, 299 |
43 |
Myozyme |
Alglucosidase alfa |
D03207 |
[1] GAA |
[4] Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism |
[1] 256 |
44 |
Myozyme (alglucosidase alfa) |
Alglucosidase alfa |
D03207 |
[1] GAA |
[4] Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism |
[1] 256 |
45 |
Myozyme 50 mg powder for concentrate for solution for infusion |
Alglucosidase alfa |
D03207 |
[1] GAA |
[4] Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism |
[1] 256 |
46 |
Myozyme® |
Alglucosidase alfa |
D03207 |
[1] GAA |
[4] Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism |
[1] 256 |
47 |
N.a. |
- |
- |
- |
- |
[8] 3, 6, 8, 13, 46, 97, 240, 256 |
48 |
Neogaa |
- |
- |
- |
- |
[1] 256 |
49 |
Phosphate |
Phosphate ion |
- |
- |
- |
[29] 2, 3, 11, 12, 13, 28, 36, 46, 49, 51, 53, 60, 62, 65, 70, 78, 81, 83, 90, 96, 97, 164, 235, 256, 283, 284, 285, 286, 299 |
50 |
Pyridostigmine |
Pyridostigmine |
D00487 |
[1] ACHE |
[2] Cholinergic synapse, Glycerophospholipid metabolism |
[4] 3, 6, 11, 256 |
51 |
Pyridostigmine bromide |
Pyridostigmine |
D00487 |
[1] ACHE |
[2] Cholinergic synapse, Glycerophospholipid metabolism |
[3] 3, 6, 256 |
52 |
Raav1-cmv-gaa (study agent) administration |
- |
- |
- |
- |
[1] 256 |
53 |
Rapamycin |
Sirolimus |
D00753 |
[1] MTOR |
[43] AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
[16] 2, 15, 34, 35, 46, 49, 51, 60, 61, 67, 86, 89, 158, 256, 278, 279 |
54 |
Recombinant human ?-glucosidase conjugated with synthetic bismannose-6-phosphate-man6 glycan |
Phosphate ion |
- |
- |
- |
[1] 256 |
55 |
Recombinant human a-glucosidase conjugated with multiple copies of synthetic bis-mannose-6-phosphate-tetra-mannose glycan (neogaa) |
Mannose |
- |
- |
- |
[1] 256 |
56 |
Recombinant human acid alfa-glucosidase (rhgaa) |
- |
- |
- |
- |
[1] 256 |
57 |
Recombinant human acid alpha-glucosidase (rhgaa) |
Alglucosidase alfa |
D03207 |
[1] GAA |
[4] Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism |
[1] 256 |
58 |
Rhgaa |
- |
- |
- |
- |
[1] 256 |
59 |
Rhgaa, acid alpha glucosidase |
Alglucosidase alfa |
D03207 |
[1] GAA |
[4] Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism |
[1] 256 |
60 |
Rituxan |
Rituximab |
D02994 |
[1] MS4A1 |
[1] Hematopoietic cell lineage |
[4] 46, 60, 256, 288 |
61 |
Rituximab |
Rituximab |
D02994 |
[1] MS4A1 |
[1] Hematopoietic cell lineage |
[42] 11, 13, 14, 17, 35, 36, 43, 44, 45, 46, 49, 50, 51, 52, 53, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 223, 229, 256, 271, 283, 284, 285, 288, 300, 331 |
62 |
Salbutamol |
Salbutamol |
D02147 |
[1] ADRB2 |
[8] Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
[8] 3, 11, 49, 85, 86, 228, 256, 299 |
63 |
Sodium valproate |
Valproic acid |
D00399 |
[7] ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 |
[17] Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism |
[4] 2, 90, 102, 256 |
64 |
Ss-hydroxybuturate esters |
- |
- |
- |
- |
[1] 256 |
65 |
Triheptanoin |
Triheptanoin |
D11465 |
- |
- |
[10] 2, 8, 120, 149, 156, 248, 256, 257, 317, 324 |
66 |
Ux007 |
- |
- |
- |
- |
[4] 8, 248, 256, 257 |
67 |
Val-1221 |
- |
- |
- |
- |
[1] 256 |
68 |
Valproate |
Valproic acid |
D00399 |
[7] ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 |
[17] Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism |
[6] 2, 3, 90, 102, 233, 256 |
69 |
Valproic acid |
Valproic acid |
D00399 |
[7] ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 |
[17] Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism |
[10] 3, 5, 26, 34, 65, 89, 90, 222, 256, 331 |
70 |
Zavesca |
Miglustat |
D05032 |
[1] UGCG |
[2] Metabolic pathways, Sphingolipid metabolism |
[3] 19, 256, 299 |
71 |
Zavesca® prescription |
- |
- |
- |
- |
[1] 256 |